Skip to main content

13.02.2019 | Glaucoma | Ausgabe 5/2019 Open Access

Graefe's Archive for Clinical and Experimental Ophthalmology 5/2019

Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma

Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 5/2019
Herbert Reitsamer, Chelvin Sng, Vanessa Vera, Markus Lenzhofer, Keith Barton, Ingeborg Stalmans, For The Apex Study Group
Wichtige Hinweise
Results from interim analyses were presented in part at: American Glaucoma Society 2016 Annual Meeting, March 3–6, 2016, Fort Lauderdale, FL, USA; American Society of Cataract and Refractive Surgery (ASCRS) Symposium and Congress, May 6–10, 2016, New Orleans, LA, USA; European Association for Vision and Eye Research Conference, October 5–8, 2016, Nice, France; and 12th European Glaucoma Society Congress, June 19–22, 2016, Prague, Czech Republic.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



To evaluate the effectiveness of an ab interno subconjunctival gelatin implant as primary surgical intervention in reducing intraocular pressure (IOP) and IOP-lowering medication count in medically uncontrolled moderate primary open-angle glaucoma (POAG).


In this prospective, non-randomized, open-label, multicenter, 2-year study, eyes with medicated baseline IOP 18–33 mmHg on 1–4 topical medications were implanted with (phaco + implant) or without (implant alone) phacoemulsification. Changes in mean IOP and medication count at months 12 (primary outcomes) and 24, clinical success rate (eyes [%] achieving ≥ 20% IOP reduction from baseline on the same or fewer medications without glaucoma-related secondary surgical intervention), intraoperative complications, and postoperative adverse events were assessed.


The modified intent-to-treat population included 202 eyes (of 218 implanted). Changes (standard deviation) in mean IOP and medication count from baseline were − 6.5 (5.3) mmHg and − 1.7 (1.3) at month 12 and − 6.2 (4.9) mmHg and − 1.5 (1.4) at month 24, respectively (all P < 0.001). Mean medicated baseline IOP was reduced from 21.4 (3.6) to 14.9 (4.5) mmHg at 12 months and 15.2 (4.2) mmHg at 24 months, with similar results in both treatment groups. The clinical success rate was 67.6% at 12 months and 65.8% at 24 months. Overall, 51.1 (12 months) and 44.7% (24 months) of eyes were medication-free. The implant safety profile compared favorably with that published for trabeculectomy and tube shunts.


The gelatin implant effectively reduced IOP and medication needs over 2 years in POAG uncontrolled medically, with an acceptable safety profile.
ClinicalTrials.​gov registration number: NCT02006693 (registered in the USA).

Unsere Produktempfehlungen

e.Med Interdisziplinär


Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Gräfes Archiv


Über diesen Artikel

Weitere Artikel der Ausgabe 5/2019

Graefe's Archive for Clinical and Experimental Ophthalmology 5/2019 Zur Ausgabe